top of page
A L T I T U D E
Life Science Ventures
Companies in the News
Dec 23, 2024
U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio’s New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer
New Drug Application (NDA) is based on pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies of taletrectinib that...
Dec 18, 2024
Tessera Therapeutics Receives Investment to Develop Curative In Vivo Genetic Treatment for Sickle Cell Disease
Investments of up to $50 million from the Bill & Melinda Gates Foundation to develop globally accessible in vivo genetic therapies for...
Dec 13, 2024
Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting
Objective response rate (ORR) of 94% and a complete response (CR) rate of 71% demonstrated after IMPT-314 treatment in CAR T-naïve...
Dec 9, 2024
Tessera Therapeutics Highlights Advances Across In Vivo Programs for Sickle Cell Disease and T-Cell Therapies at the 66th American Society of Hematology Annual Meeting
In vivo proof-of-concept achieved in humanized mice and non-human primates (NHPs) using Gene Writers encapsulated in proprietary lipid...
bottom of page